Most Recent
In plea to court, Mayfair’s Mawhinney tries to salvage Mission Beach investments
The director of the besieged Mayfair investment group will submit a new noteholder proposal to the court in an effort to stave off the winding up of M101 Nominees and salvage his multi-million dollar Dunk Island and Mission Beach investments.
S&P class action applicant wants to look at other applicant’s funding agreement
One of the lead applicants in a class action against ratings giant S&P Global, which is involved in a dispute with the funder that's backing the case, wants to look at the funding agreement signed by the class action's other lead applicant.
‘An act of bad faith’: Network Ten hit with indemnity costs after hiding defamation notice
A court has hit Network Ten with indemnity costs after finding the broadcaster "buried" a defamation notice on its website in a manner designed to "frustrate or undermine" a settlement agreement reached with a gay American social media personality.
Boehringer appeals win for Merck in parasite patent spat
Pharmaceutical company Boehringer Ingelheim will take another crack at opposing a patent application for an injectable anti-parasite drug for livestock by a subsidiary of competitor Merck Sharp & Dohme.
Hiding name of buyer in Antares oil deal a breach of disclosure obligations, court says
In a win for ASIC, a judge has found that former oil and gas company Antares Energy violated its continuous disclosure obligations by failing to reveal the name of the buyer behind an ill-fated US$254 million acquisition of Texan oil assets.
ATO wins appeal in $60M tax dispute with Healius
The Australian Taxation Office has secured a Full Federal Court victory in its $60 million tax battle with Healius, overturning a ruling that found the healthcare company could claw back a multi-million dollar tax refund.
Arrow drops opposition to Novartis patent for MS drug, despite win before IP Australia
The Federal Court has upheld Novartis' appeal of a ruling revoking its patent for an oral form of multiple sclerosis drug Gilenya, after Australian generic drug maker Arrow Pharmaceuticals dropped its opposition to the patent despite prevailing before IP Australia.
AMP hits back at class action, says buy-out policy changes needed to avoid ‘BOLR run’
Changes to AMP's buyer of last resort policy that reduced the multiple by which the wealth management firm would purchase advisers' client registers was necessary to protect the business from a 'BOLR run', a court had been told.
Delegate deflates Ann Taylor’s opposition to Nike’s ‘Aeroloft’ trade mark
US women's clothing retailer Ann Taylor has come up short in its opposition to Nike's bid to register the 'Aeoroloft' mark for its brand of lightweight fitness apparel, with an IP Australia finding the mark is not deceptively similar to Ann Taylor's 'Loft' mark.
Zip Co crushes Flexigroup’s ‘No Interest’ trade mark
Fintech Zip Co has successfully opposed rival Flexigroup's attempt to trade mark 'No Interest Ever!', in the latest trade mark battle between buy now, pay later service providers in Australia.